(19) World Intellectual Property Organization International Bureau





(43) International Publication Date. 9 October 2003 (09.10.2003)

(10) International Publication Number WO 03/083096 A3

- (51) International Patent Classification7: C12N 9/12. G01N 33/50, C12Q 1/68, A61K 38/00, 39/00, A61P 35/00
- (21) International Application Number: PCT/CA03/00409
- (22) International Filing Date: 21 March 2003 (21.03.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/368,853

28 March 2002 (28.03.2002)

- (71) Applicant (for all designated States except US): KINETEK PHARMACEUTICALS, INC. [CA/CA]; 1779 West 75th Avenue, Vancouver, British Columbia V6P 6P2 (CA).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): DELANEY, Allen, D. [CA/CA]; 1633 West 65th Avenue, Vancouver, British Columbia V6P 2R2 (CA).
- (74) Agents: KINGWELL, Brian, G. et al.; Smart & Biggar, Suite 2200, 650 West Georgia Street, Box 11560, Vancouver Center (CA).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 27 November 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CANCER ASSOCIATED PROTEIN KINASES AND THEIR USES

(57) Abstract: Detection of expression of the provided protein kinase in cancers is useful as a diagnostic, for determining the effectiveness of drugs, and determining patient prognosis. The encoded polypeptides further provide a target for screening pharmaceutical agents effective in inhibiting the growth or metastasis of tumor cells. The present invention further provides methods and compositions relating to agents that specifically bind to HSM801163, PCTK3, PFTK1, CRK7, PRKCN, CIT, STK6, PDK1, PAK4, ITK, BMX, PRKCM, NEK6 or PDPK1 for treatment and visualization of tumors in patients.

" nal Application No PL., JA 03/00409

A. CLASSIFICATION OF SUBJECT MATTER
1PC 7 C12N9/12 G01N33/50 A61K39/00 A61K38/00 C12Q1/68 A61P35/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C12N G01N C12Q A61K A61P IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, Sequence Séarch C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages 1-57 WO 00 06728 A (INCYTE PHARMA INC) Χ 10 February 2000 (2000-02-10) page 24, line 20 - line 27 page 25, line 29 - line 31 page 28, line 26 - page 30, line 2 SEQ ID NO:5; SEQ ID NO:26 page 32, line 33 - page 37, line 32 WO 01 53312 A (HYSEQ INC (US))
26 July 2001 (2001-07-26)
SEQ ID N0:320; SEQ ID N0:2106
page 20, line 24 - page 24, line 12
page 28, line 11 - line 17 1-57 χ page 20, line 11 - line 17
page 34, line 8 - page 38, line 15
page 52, line 32 - page 54, line 26
page 55, line 30 - page 57, line 3
page 74, line 5 - page 84, line 25
page 87, line 12 - page 91, line 8 Patent family members are listed in annex. Further documents are listed in the continuation of box C. "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the leverities." Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance Invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "E" earlier document but published on or after the international "L." document which may throw doubts on priority daim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "O" document relerring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 1 5. 10. 2003 17 June 2003 Authorized officer Name and mailing address of the ISA European Patent Ollice, P.8. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

Schönwasser, D.

Form PCT/ISA/210 (second sheet) (July 1992)

Int 1al Application No F.,, A 03/00409

		Fun, A 03/00409
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	. Relevant to daim No.
(WO 01 81555 A (INCYTE GENOMICS INC.) 1 November 2001 (2001-11-01) SEQ ID NO:13; SEQ ID NO:31	1-57
	MEYERSON M ET AL: "A family of human cdc2-related protein kinases" EMBO JOURNAL, vol. 11, no. 8, 1992, pages 2909-2917, XP002128265 ISSN: 0261-4189 cited in the application figure legend of Fig. 1, line 5	1,14
1	"PCTAIRE-3, X66362"figure 1	
,х	US 6 500 938 B1 (SEILHAMER JEFFREY J ET AL) 31 December 2002 (2002-12-31) SEQ ID NO:1283, page 65; [0006]-[0008];[0079]; [0082]-[0083]	1-57
, X	WO 02 101357 A (IRM LLC) 19 December 2002 (2002-12-19) [0017]-[0025] page 46, line 8	1-57

Form PCT/ISA/210 (confinuation of second sheet) (July 1992)

ional application No. PCT/CA 03/00409

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)	1
Box I Observations where certain claims were round disease.	1
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:	
2. X Claims Nos.: 15-57 (incomplete) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: See FURTHER INFORMATION sheet PCT/ISA/210	
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	
This International Searching Authority found multiple inventions in this international application, as follows:	
see additional sheet	
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.	
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:	
4. X No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-57 (all partially)	
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.	
page 1 of 2	

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 15-57 (incomplete)

Present claims 15-57 relate to an extremely large number of possible compounds of the general formula alpha(Pz)C or alpha(Pz) whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds of the general formula alpha(Pz)C or alpha(Pz) as defined on page 15, line 34 to page 21, line 30, namely to antibodies which specifically bind the claimed proteins with or without a cytotoxic moiety.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-57 (all partially)

Invention 1:

A method of screening for biologically active agents that modulate a cancer associated protein kinase function involving a polypeptide encoded by SEQ ID NO:1 or having the amino acid sequence set forth in SEQ ID NO:2 (PCTK3) and subject-matter relating thereto.

2. claims: 1-57 (all partially)

Inventions 2-14:

Invention 2-14 relates to subject-matter as defined above for "invention 1", with the exception, that each of the inventions 2-14 refers to on eof the amino acid sequence SEQ ID NO:4,6,8,10,12,14, 16,18,20,22,24,26, respecitively and the to the corresponding nucleic acid sequence SEQ ID NO:3,5,7,9,11,13,15,17,19,21,23,25,27.

Iformation on patent family members

Intr----nal Application No
Pull CA 03/00409

	ent document n search report		Publication date		Patent family member(s)	Publication date
WO 0	9006728	A	10-02-2000	AU	5134999 A	21-02-2000
				CA	2335644 A1	10-02-2000
				EP	1100904 A2	23-05-2001
				. WO	. 0006728 A2	10-02-2000
				JP	2002526035 T	20-08-2002
WO (0153312	A	26-07-2001	US	6569662 81	27-05-2003
				AU	2292401 A	31-07-2001
				AU	2591801 A	31-07-2001
				AU	2593601 A	31-07-2001
				AU	2595501 A	31-07-2001
				AU	2596501 A	31-07-2001
				AU	2598301 A	31-07-2001
				AU	2728401 A	31-07-2001
				AU	2734401 A	31-07-2001
				AU	2734801 A	31-07-2001 31-07-2001
				AU AU	2738501 A 3265701 A	31-07-2001
				CA	2395443 A1	26-07-2001
				CA	2395731 A1	26-07-2001
				CA	2395731 AI 2395736 AI	26-07-2001
				CA	2395749 A1	26-07-2001
				CA	2395763 A1	26-07-2001
				CA	2395770 A1	26-07-2001
				CA	2402563 A1	26-07-2001
				EP	1242596 A1	25-09-2002
				EP	1240178 A2	18-09-2002
				EP	1242580 A1	25-09-2002
				EP	1242443 A1	25-09-2002
				EP	1250346 A2	23-10-2002
				EP	1254256 A2	06-11-2002
				EP	1248848 A1	16-10-2002
				WO	0153312 A1	26-07-2001
				WO WO	0153453 A2 0153326 A1	26-07-2001 26-07-2001
			•	WO WO	0153326 A1 0153454 A2	26-07-2001
				WO	0153454 AZ 0153455 A2	26-07-2001
				WO	0153456 A2	26-07-2001
				MO	0153456 A2	26-07-2001
				WO	0152616 A2	26-07-2001
				WO	0153500 A1	26-07-2001
				WO	0153515 A1	26-07-2001
				WO	0153485 A1	26-07-2001
				US	2003104529 A1	05-06-2003
				US	6586390 B1	01-07-2003
				US	6465620 B1	15-10-2002
				US ·	2002146692 A1	10-10-2002
				AU	5362001 A	30-10-2001
				CA	2406039 A1	25-10-2001
				EP	1276754 A2	22-01-2003
	•			WO	0179446 A2	25-10-2001
				US US	2002197679 A1 2002142953 A1	26-12-2002 03-10-2002
WO 0	101555		27-06-2002		5557301 A	07-11-2001
	0181555	Α	21-00-2002	AU CA	2406399 A1	01-11-2001
no c				LH	とみいいつファ ガエ	01-11-5001
110				EP	1297150 A2	02-04-2003

ormation on patent family members

Inte	" nal Application No	
	LI/CA 03/00409	

Patent document cited in search report		Publication date		Patent family member(s)	. Publication date
WO 0181555	A		US	2002026226 A1	28-02-2002
US 6500938	B1	31-12-2002	NONE		
WO 02101357	Α	19-12-2002	WO US	02101357 A2 2003138793 A1	19-12-2002 24-07-2003